Eli Lilly’s Lebrikizumab Shows Positive Phase 3 Results for Atopic Dermatitis

Eli Lilly’s IL-13 inhibitor lebrikizumab significantly improved disease severity when combined with topical corticosteroids in people with moderate-to-severe atopic dermatitis (AD) in the drug’s third pivotal phase 3 trial, the company said.
Source: Drug Industry Daily